Cargando…
Crosstalk between Statins and Cancer Prevention and Therapy: An Update
The importance of statins in cancer has been discussed in many studies. They are known for their anticancer properties against solid tumors of the liver or lung, as well as diffuse cancers, such as multiple myeloma or leukemia. Currently, the most commonly used statins are simvastatin, rosuvastatin...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704600/ https://www.ncbi.nlm.nih.gov/pubmed/34959621 http://dx.doi.org/10.3390/ph14121220 |
_version_ | 1784621745600200704 |
---|---|
author | Grabarek, Beniamin Oskar Boroń, Dariusz Morawiec, Emilia Michalski, Piotr Palazzo-Michalska, Veronica Pach, Łukasz Dziuk, Barbara Świder, Magdalena Zmarzły, Nikola |
author_facet | Grabarek, Beniamin Oskar Boroń, Dariusz Morawiec, Emilia Michalski, Piotr Palazzo-Michalska, Veronica Pach, Łukasz Dziuk, Barbara Świder, Magdalena Zmarzły, Nikola |
author_sort | Grabarek, Beniamin Oskar |
collection | PubMed |
description | The importance of statins in cancer has been discussed in many studies. They are known for their anticancer properties against solid tumors of the liver or lung, as well as diffuse cancers, such as multiple myeloma or leukemia. Currently, the most commonly used statins are simvastatin, rosuvastatin and atorvastatin. The anti-tumor activity of statins is largely related to their ability to induce apoptosis by targeting cancer cells with high selectivity. Statins are also involved in the regulation of the histone acetylation level, the disturbance of which can lead to abnormal activity of genes involved in the regulation of proliferation, differentiation and apoptosis. As a result, tumor growth and its invasion may be promoted, which is associated with a poor prognosis. High levels of histone deacetylases are observed in many cancers; therefore, one of the therapeutic strategies is to use their inhibitors. Combining statins with histone deacetylase inhibitors can induce a synergistic anticancer effect. |
format | Online Article Text |
id | pubmed-8704600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87046002021-12-25 Crosstalk between Statins and Cancer Prevention and Therapy: An Update Grabarek, Beniamin Oskar Boroń, Dariusz Morawiec, Emilia Michalski, Piotr Palazzo-Michalska, Veronica Pach, Łukasz Dziuk, Barbara Świder, Magdalena Zmarzły, Nikola Pharmaceuticals (Basel) Review The importance of statins in cancer has been discussed in many studies. They are known for their anticancer properties against solid tumors of the liver or lung, as well as diffuse cancers, such as multiple myeloma or leukemia. Currently, the most commonly used statins are simvastatin, rosuvastatin and atorvastatin. The anti-tumor activity of statins is largely related to their ability to induce apoptosis by targeting cancer cells with high selectivity. Statins are also involved in the regulation of the histone acetylation level, the disturbance of which can lead to abnormal activity of genes involved in the regulation of proliferation, differentiation and apoptosis. As a result, tumor growth and its invasion may be promoted, which is associated with a poor prognosis. High levels of histone deacetylases are observed in many cancers; therefore, one of the therapeutic strategies is to use their inhibitors. Combining statins with histone deacetylase inhibitors can induce a synergistic anticancer effect. MDPI 2021-11-25 /pmc/articles/PMC8704600/ /pubmed/34959621 http://dx.doi.org/10.3390/ph14121220 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Grabarek, Beniamin Oskar Boroń, Dariusz Morawiec, Emilia Michalski, Piotr Palazzo-Michalska, Veronica Pach, Łukasz Dziuk, Barbara Świder, Magdalena Zmarzły, Nikola Crosstalk between Statins and Cancer Prevention and Therapy: An Update |
title | Crosstalk between Statins and Cancer Prevention and Therapy: An Update |
title_full | Crosstalk between Statins and Cancer Prevention and Therapy: An Update |
title_fullStr | Crosstalk between Statins and Cancer Prevention and Therapy: An Update |
title_full_unstemmed | Crosstalk between Statins and Cancer Prevention and Therapy: An Update |
title_short | Crosstalk between Statins and Cancer Prevention and Therapy: An Update |
title_sort | crosstalk between statins and cancer prevention and therapy: an update |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704600/ https://www.ncbi.nlm.nih.gov/pubmed/34959621 http://dx.doi.org/10.3390/ph14121220 |
work_keys_str_mv | AT grabarekbeniaminoskar crosstalkbetweenstatinsandcancerpreventionandtherapyanupdate AT borondariusz crosstalkbetweenstatinsandcancerpreventionandtherapyanupdate AT morawiecemilia crosstalkbetweenstatinsandcancerpreventionandtherapyanupdate AT michalskipiotr crosstalkbetweenstatinsandcancerpreventionandtherapyanupdate AT palazzomichalskaveronica crosstalkbetweenstatinsandcancerpreventionandtherapyanupdate AT pachłukasz crosstalkbetweenstatinsandcancerpreventionandtherapyanupdate AT dziukbarbara crosstalkbetweenstatinsandcancerpreventionandtherapyanupdate AT swidermagdalena crosstalkbetweenstatinsandcancerpreventionandtherapyanupdate AT zmarzłynikola crosstalkbetweenstatinsandcancerpreventionandtherapyanupdate |